Results 31 to 40 of about 993 (163)

Candida auris: a review of global epidemiology, multidrug resistance, and infection control in healthcare-associated outbreaks [PDF]

Frontiers in Cellular and Infection Microbiology
Candida auris, designated a critical-priority fungal pathogen by the World Health Organization, poses a growing threat to healthcare systems worldwide. Analysis of 80 peer-reviewed studies reveals five principal findings: (1) C.
Xuewei Du, Li Li
doaj   +2 more sources

Cost-Effectiveness of Once Weekly Rezafungin for the Treatment of Invasive Candidiasis in the United Kingdom. [PDF]

Mycoses
ABSTRACT Background Invasive candidiasis (IC), life‐threatening fungal infections with high economic burden, are often treated first‐line with daily intravenous echinocandins. A new once weekly echinocandin, rezafungin, demonstrated statistically non‐inferior efficacy and numerically shorter intensive care unit (ICU) stay compared to caspofungin in ...
Muszbek N, Angdembe A, Garcia-Vidal C, Bielicka I, Abrams KR, Tolley K, Ruhnke M, Lebmeier M, Hawkins N, Manamley N, Dickerson S.   +10 more
europepmc   +2 more sources

Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real-World Clinical Practice. [PDF]

Mycoses
ABSTRACT Background Echinocandins are the first‐line treatment for invasive candidiasis. Rezafungin is a novel echinocandin with improved pharmacokinetic properties that allow for once‐weekly intravenous administration, offering potential advantages in complex clinical settings.
Boán J, Aparicio-Minguijón E, Fernández-Ruiz M, Pérez-Jacoiste Asín MA, Rodríguez-Goncer I, López-Medrano F, San-Juan R, Silva JT, Pérez-Ayala A, Caro-Teller JM, Aguado JM.   +10 more
europepmc   +2 more sources

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin [PDF]

Drugs, 2021
The epidemiology of invasive fungal infections is changing, with new populations at risk and the emergence of resistance caused by the selective pressure from increased usage of antifungal agents in prophylaxis, empiric therapy, and agriculture. Limited antifungal therapeutic options are further challenged by drug-drug interactions, toxicity, and ...
Martin Hoenigl, Rosanne Sprute, Matthias Egger, Amir Arastehfar, Oliver A. Cornely, Robert Krause, Cornelia Lass-Flörl, Juergen Prattes, Andrej Spec, George R. Thompson, Nathan Wiederhold, Jeffrey D. Jenks   +11 more
openaire   +4 more sources

Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: Pooled data from two prospective randomised controlled trials [PDF]

, 2023
BACKGROUND: Rezafungin, a new US Food and Drug Administration-approved, long-acting echinocandin to treat candidaemia and invasive candidiasis, was efficacious with a similar safety profile to caspofungin in clinical trials.
et al.,, Kollef, Marin, Thompson, George R, 3rd   +2 more
core   +3 more sources

Efficacy and Safety of Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis in a China Cohort of a Double-Blind, Randomised, Phase 3 Trial (ReSTORE China). [PDF]

Mycoses
ABSTRACT Background The global double‐blind, randomised, Phase 3 ReSTORE trial (NCT03667690) demonstrated noninferiority of rezafungin versus caspofungin for all‐cause mortality at Day 30 and global cure at Day 14 in patients with candidemia and/or invasive candidiasis.
Huang H, Feng S, Yu Y, Zhang Y, Yuan Y, Cox L, Zhang Y.   +6 more
europepmc   +2 more sources

Successful outpatient parenteral antimicrobial therapy with rezafungin for chronic pulmonary aspergillosis: a case report and health economic assessment. [PDF]

JAC Antimicrob Resist
Background: Chronic pulmonary aspergillosis (CPA) is a serious lung disorder caused by Aspergillus fungal infection with high morbidity and mortality. Treatment options include antifungal azoles, polyenes and echinocandins.
Law SM, Choyce A, Barzinji H, Ellis H, Kosmidis C, Seaton RA.   +5 more
europepmc   +2 more sources

Promising antimycotics for the treatment of invasive infections [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2023
This paper provides a review of the largest studies (over the period of 2018 to 2023) of promising novel antimycotics and their possible role in the treatment of invasive mycoses, including infections caused by resistant Candida and Aspergillus isolates.
Ortenberg E.А.
doaj   +1 more source

A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects

Clinical and Translational Science, 2022
Rezafungin is a novel echinocandin being developed for the treatment and prevention of invasive fungal infections. The objectives of this randomized, double‐blind study in healthy adults were to determine the safety, tolerability, and pharmacokinetics of
Kenan Gu, Dennis Ruff, Cassandra Key, Marissa Thompson, Shoshanna Jiang, Taylor Sandison, Shawn Flanagan   +6 more
doaj   +1 more source

Efficacy of Rezafungin on <i>Candida albicans</i> Endophthalmitis in a Rabbit Model. [PDF]

Pathog Immun
Background: Endophthalmitis, a severe infection of the intraocular tissues that can result in permanent loss of vision if not immediately treated, is often caused by fungi, namely Candida albicans. Treatment options are limited due to a lack of ocular penetration of antifungal drugs.
Saghir J, Herrada J, Long L, Valentin ES, McCormick TS, Ghannoum M.   +5 more
europepmc   +3 more sources